Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Rap4.5
Rapamycin – Forschung
Überwiegend Mechanismus / Beobachtung
12 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Rapamycin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 218 Teilnehmenden.
Basierend auf 12 Studien · 1 Meta-Analyse · 2 RCTs · 242 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Lifespan & aging (preclinical)In Tierstudien speziesübergreifend die am robustesten lebensverlängernde Substanz; ein Langlebigkeitsnutzen beim Menschen ist unbewiesen (die Daten stammen aus kurzfristigen Immun-/Biomarker-Studien) · Beim Menschen unbekannt
Überwiegend Mechanismus / Beobachtung8 Studien
Immune functionKurzfristige mTOR-Hemmung verbesserte in randomisierten Studien die Impfantwort und Immunfunktion bei älteren Erwachsenen (kontinuierliche Gabe unterdrückt hingegen die Immunität) · Wochen
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Aktives Forschungsgebiet
6 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2017
200920172026
1Systematische Übersicht2026
Sirolimus is an effective targeted therapy for refractory slow- flow vascular malformations but should not be considered a universal treatment for all vascular anomalies.
Santos PM et al. · Portuguese journal of cardiac thoracic and vascular surgery (2026)
Sirolimus demonstrates high response rates in slow- flow malformations, with partial responses in approximately 60-85%60-85% of patients and clinically meaningful improvements in health- related quality of life (HRQoL).
Sirolimus is an effective targeted therapy for refractory slow- flow vascular malformations but should not be considered a universal treatment for all vascular anomalies.
Future directions include molecularly guided therapy, rational combination regimens and integration with PI3K- and AKT- directed agents.
Targeted modulation of macrophage metabolism offers a new direction for individualized immunometabolic therapy in sepsis.
Zhao T et al. · International journal of molecular medicine (2026)
In view of the 31.5% global mortality (21.4 million mortalities in 2021) caused by sepsis, a shift from supportive treatment to precise immune metabolism intervention is needed.
The present article uniquely integrates the coordinated regulation of glucose, lipid and amino acid metabolic networks of macrophages in sepsis, and expounds the research status of immune metabolism in sepsis, in order to provide reference for the clinical treatment of sepsis.
Targeted modulation of macrophage metabolism offers a new direction for individualized immunometabolic therapy in sepsis.
Understanding this redox paradox is critical to exposing therapeutic vulnerabilities and improving outcomes for patients with these deadly cancers.
Kumari P et al. · Trends in cancer (2026)
Targeting ROS is challenging; however, new strategies, including NADPH oxidase inhibition, metabolic modulation, and ROS-inducing therapies, reveal vulnerabilities.
Understanding this redox paradox is critical to exposing therapeutic vulnerabilities and improving outcomes for patients with these deadly cancers.
Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. · Journal of cachexia, sarcopenia and muscle (2026)
Methods In this randomised, double-blind, placebo-controlled trial, 40 sedentary adults aged 65-85 years (mean 72.2 years; 47.5% female) were assigned (1:1) to sirolimus (rapamycin) 6 mg or matched placebo once weekly for 13 weeks.
The primary intention-to-treat analysis showed an adjusted mean difference (sirolimus-placebo) of -2.13 repetitions (95% CI -4.61 to 0.34; p = 0.089).
Secondary functional outcomes also favoured placebo but were not statistically significant: the adjusted mean difference for 6MWD was -4.87 m (95% CI -28.97 to 19.71; p = 0.706) and for grip strength was -1.13 kg (95% CI -3.52 to 1.18; p = 0.344).
Low dose rapamycin therapy has been proposed as a longevity candidate in healthy aging adults.
We present a review of the evidence for low dose rapamycin and rapalog therapies in healthy human adults and model the findings of one cohort study using the PhenoAge model.
Despite the preclinical evidence supporting the use of sirolimus to enhance mean and maximal lifespan, the data in humans have yet to establish that rapamycin, or its analogues, is a proven seno-therapeutic that can delay aging in healthy older adults.